Google
PRQR — PROQR THERAPEUTICS BV (Healthcare >> Biotechnology)
PRQR FAQ
What is PRQR's ROE?
PROQR THERAPEUTICS BV reports a Return on Equity (ROE) of -121.22%.
What is PRQR's dividend yield?
PROQR THERAPEUTICS BV offers a dividend yield of 0.00%.
What is PRQR's Deepscope Quality Score?
Deepscope rates PRQR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PRQR?
Deepscope's AI Timing Score for PRQR is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PRQR belong to?
PROQR THERAPEUTICS BV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.50
Price
-0.03
(-1.96%)
Day Change
|
|
|---|
PRQR, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.50 |
| PBV / Sector |
4.20 / 4.63
|
| Earning Per Share | -0.43 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.88 M
GREAT
|
| Average 1W Daily Value |
1.05 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PRQR |
| Name | PROQR THERAPEUTICS BV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 105.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 158.04 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Zernikedreef 9, Leiden, Netherlands, 2333 CK
Phone: 31 88 166 7000
Website: https://www.proqr.com
Employees: 186
Sector: Healthcare >> Biotechnology
Description: ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
